Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tisotumab vedotin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| tisotumab vedotin | DRUG | Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Tisotumab vedotin is an investigational oncology drug being studied for the treatment of solid tumors. It is currently in Phase 2 clinical development. The drug is being evaluated in patients with advanced solid malignancies, as part of a clinical trial program.
Tisotumab vedotin is being developed by Genmab A/S, a biopharmaceutical company. Genmab's stock is traded under the ticker symbol GMAB. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with solid tumors.
Tisotumab vedotin is in Phase 2 clinical development for the treatment of solid tumors. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in clinical trials to determine its safety and effectiveness.
Tisotumab vedotin has been studied in a clinical trial with the identifier NCT03913741, titled 'A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies.' This trial was a Phase 1/Phase 2 study that has been completed, with a total enrollment of 23 participants.
Tisotumab vedotin is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for solid tumors. The drug has not yet received regulatory approval and is still being evaluated in clinical trials to assess its safety and efficacy.